You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 153 No. 3, 8 FEB 1993 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Investigations
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (39)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Superior Vena Cava Syndrome in Small-cell Lung Cancer

Thierry Urban, MD; Bernard Lebeau, MD; Claude Chastang, MD, PhD; Pascal Leclerc, MD; Marie José Botto, MD; Joseph Sauvaget, MD

Arch Intern Med. 1993;153(3):384-387.


Abstract



Background
The aim of this study was to analyze the features of the superior vena cava syndrome (SVCS) as initial characteristics in small-cell lung cancer: incidence, dissemination of disease, diagnostic procedures, efficacy and toxic effects of chemotherapy, and median survival in patients with SVCS.

Methods
In a prospective series of 724 patients with biopsy-proved small-cell lung cancer seen during a 6-year period, we reviewed data from patients who also had SVCS.

Results
The incidence of SVCS was 87 of 724 at the time of diagnosis. Initial emergency radiation therapy was not used in these patients. Diagnostic procedures in these patients were not associated with mortality. Rapid initiation of intensive chemotherapy, often with heparin therapy, resulted in complete or partial responses in 81% and no response in 12%; data were not evaluable in 7%. Two of these 87 patients died of aplasia within 4 weeks of chemotherapy. Median survival was not significantly different in the patients with SVCS (median, 42 weeks) and without SVCS (median, 40 weeks). A significant increase in initial brain metastases at the time of diagnosis was observed in patients with SVCS (22% vs 11%).

Conclusions
Intensive chemotherapy is the first line of therapy in small-cell lung cancer. Histologic diagnostic procedures must be performed in patients with SVCS to adapt the treatment to the underlying cause. Initial emergency radiotherapy, before diagnosis or chemotherapy, does not seem to be useful in these patients. Computed tomography of the brain should be performed routinely in patients with SVCS, and prophylactic brain irradiation could be helpful in such patients. Apparently SVCS is not a poor prognostic factor in treated small-cell lung cancer.

(Arch Intern Med. 1993;153:384-387)



Author Affiliations



From the Pulmonary Departments, Hôpital Saint-Antoine, Paris, France (Drs Urban, Lebeau, Leclerc, Botto, and Sauvaget), Centre Hospitalier Général, Saint-Germain en Laye, France (Dr Leclerc), Centre Hospitalier, Creil, France (Dr Botto), and Hôpital Saint Joseph, Paris (Dr Sauvaget); and the Biostatistic and Medical Informatic Department, Hôpital Saint-Louis, Paris (Dr Chastang).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Stenting the Superior Vena Cava Syndrome in Patients With Malignant Disease
Cho et al.
ANGIOLOGY 2011;62:248-252.
ABSTRACT  

Macrolides and lower respiratory tract infections
Dorca et al.
Thoracic Malignancies 2010;1:78-93.
ABSTRACT  

Endovascular Stenting as the First Step in the Overall Management of Malignant Superior Vena Cava Syndrome
Lanciego et al.
Am. J. Roentgenol. 2009;193:549-558.
ABSTRACT | FULL TEXT  

Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Kvale et al.
Chest 2007;132:368S-403S.
ABSTRACT | FULL TEXT  

Use of self-expanding vascular endoprostheses in superior vena cava syndrome
Garcia Monaco et al.
Eur J Cardiothorac Surg 2003;24:208-211.
ABSTRACT | FULL TEXT  

Stenting as First Option for Endovascular Treatment of Malignant Superior Vena Cava Syndrome
Lanciego et al.
Am. J. Roentgenol. 2001;177:585-593.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.